Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of
partial-onset seizures. Structurally, it belongs to the dibenzazepine family and is closely …

Abstract Eslicarbazepine acetate (Aptiom®, Zebinix®) is approved for the adjunctive
treatment of partial-onset seizures in adults aged≥ 18 years. Adjunctive therapy with oral …

Eslicarbazepine is a new dibenzazepine antiepileptic agent. It is a high affinity antagonist of
the voltage-gated sodium channel. It is closely related to both carbamazepine and …

Eslicarbazepine acetate is a is a once-daily antiepileptic drug (AED) that was approved in
2009 by the European Medicines Agency (EMA)(Zebinix™), and in 2013 by the US Food …

Purpose: To evaluate the long‐term efficacy and safety of once daily eslicarbazepine
acetate (ESL) as adjunctive therapy for partial‐onset seizures in adults with epilepsy …

Background: Epilepsy is a neurological condition with an increased probability of seizure
occurrence through time. Although many anti-epileptic drugs (AEDs) exist, they fail to treat …

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Objective: To explore the efficacy and safety of eslicarbazepine acetate (BIA 2‐093), a new
antiepileptic drug, as adjunctive therapy in adult patients with partial epilepsy. Methods: A …